These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 32163385)
1. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer]. Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385 [TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658 [TBL] [Abstract][Full Text] [Related]
3. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors. Tang XY; Ding YS; Zhou T; Wang X; Yang Y Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650 [TBL] [Abstract][Full Text] [Related]
4. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525 [TBL] [Abstract][Full Text] [Related]
5. The emerging field of oncolytic virus-based cancer immunotherapy. Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738 [TBL] [Abstract][Full Text] [Related]
6. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314 [TBL] [Abstract][Full Text] [Related]
7. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy. McGrath K; Dotti G Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123 [TBL] [Abstract][Full Text] [Related]
8. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment. Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315 [TBL] [Abstract][Full Text] [Related]
10. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. Guedan S; Alemany R Front Immunol; 2018; 9():2460. PubMed ID: 30405639 [TBL] [Abstract][Full Text] [Related]
11. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319 [TBL] [Abstract][Full Text] [Related]
12. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells. Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509 [TBL] [Abstract][Full Text] [Related]
13. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626 [TBL] [Abstract][Full Text] [Related]
14. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553 [TBL] [Abstract][Full Text] [Related]
15. Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies. Gao X; Liu J; Sun R; Zhang J; Cao X; Zhang Y; Zhao M Ann Hematol; 2024 Aug; 103(8):2569-2589. PubMed ID: 37853078 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Evgin L; Kottke T; Tonne J; Thompson J; Huff AL; van Vloten J; Moore M; Michael J; Driscoll C; Pulido J; Swanson E; Kennedy R; Coffey M; Loghmani H; Sanchez-Perez L; Olivier G; Harrington K; Pandha H; Melcher A; Diaz RM; Vile RG Sci Transl Med; 2022 Apr; 14(640):eabn2231. PubMed ID: 35417192 [TBL] [Abstract][Full Text] [Related]
18. Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses. Zarezadeh Mehrabadi A; Roozbahani F; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Esmaeili Gouvarchin Ghaleh H World J Surg Oncol; 2022 Jan; 20(1):16. PubMed ID: 35027068 [TBL] [Abstract][Full Text] [Related]
19. A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept. Mahasa KJ; Ouifki R; Eladdadi A; Pillis L Math Biosci Eng; 2022 Mar; 19(5):4429-4457. PubMed ID: 35430822 [TBL] [Abstract][Full Text] [Related]
20. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Crupi MJF; Bell JC; Singaravelu R Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]